Evaluation of the criteria for renewal of LHRH agonists in patients with prostate cancer: results of the ANAREN Study

• 主要な著者: Jesús Calleja-Escudero (著者), Víctor Barrondo (著者), Andrés Rodriguez-Alonso (著者), Francisco Gómez-Veiga (著者), Joan Bestard (著者), Antonio Gómez-Caamaño (著者), Anne-Sophie Grandoulier (著者), Maria Pérez-Sampietro (著者), Venancio Chantada-Abal (著者), Raúl Poza de Celis (著者), on behalf of ANAREN Study Group (著者)
• フォーマット: 図書
• 出版事項: BioExcel Publishing Ltd, 2024-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: Injectable extended-release formulations of luteinizing hormone-releasing hormone agonists (LHRHa) have simplified the treatment of prostate cancer with a satisfactory level of androgen castration. This study aims to determine the percentage of patients whose initial LHRHa prescription...